Uncategorized
Anti-VEGF improves vision up to 1 year in patients with macular edema due to CRVO
Monthly intravitreal aflibercept injections significantly improved visual acuity in patients with macular edema secondary to central retinal vein occlusion at 24 weeks, according to a study. As-needed dosing then extended the improvement through 52 weeks.The COPERNICUS study, a phase 3 randomized multicenter trial, included 189 patients with macular edema secondary to CRVO. For 24 weeks, 115 patients underwent six monthly intravitreal injections of 2-mg Eylea (aflibercept, Regeneron), and 74 patients underwent sham treatment under the same protocol.